Bone grafting

Global Bone Grafts and Substitutes Market Report to 2030 - Key Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 9, 2022
Surgery, Health, Epidemiology, Region, Bone grafting, Investment, ASP, Market access, Review, COVID-19, SWOT analysis, Internet, Country, Substitute, Reading, LIBOR market model, Retail, Marketing, Forecast

The model discusses in detail the impact of COVID-19 on Bone Grafts and Substitutes Devices market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Bone Grafts and Substitutes Devices market for the year 2020 and beyond.
  • This model is required reading for:
    The model will enable you to:
    Understand the impact of COVID-19 on Bone Grafts & Substitutes market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Bone Grafts & Substitute market in the future.
  • Track device sales in the global and country-specific Bone Grafts & Substitutes market from 2015-2030.

Insights on the Bone Grafts & Substitutes Global Market to 2027 - Increasing Demand from Orthopedic Surgeries Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, June 6, 2022
Genetics, Health, Surgery, Use, Value, Compound annual growth rate, Bone grafting, Market share analysis, Decision-making, R, Investment, Strategic management, Synthetic, Growth, Technology, Acquisition, COVID-19, Certification, Business Growth Fund, Customer support, CAGR, USD, Retail, Cultured pearl, Allotransplantation

What are the inhibiting factors and impact of COVID-19 shaping the Global Bone Grafts & Substitutes Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Bone Grafts & Substitutes Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Bone Grafts & Substitutes Market?
  • What is the market share of the leading vendors in the Global Bone Grafts & Substitutes Market?
  • What modes and strategic moves are considered suitable for entering the Global Bone Grafts & Substitutes Market?

HSS Interactive Case Lecture Highlights Practical Solutions In Shoulder Arthroplasty For Substantial Glenoid Bone Loss

Retrieved on: 
Friday, September 3, 2021
Surgery, Medical specialties, Medicine, Prosthetics, Hospital for Special Surgery, Orthopedic surgery, Reverse shoulder replacement, Arthroplasty, Knee replacement, Bone grafting, Shoulder, Glenoid fossa

The glenoid is the socket part of the shoulder joint that connects to the ball of the upper arm bone.

Key Points: 
  • The glenoid is the socket part of the shoulder joint that connects to the ball of the upper arm bone.
  • Glenoid bone loss can occur due to severe arthritis, traumatic injury or repetitive overuse in sports like baseball or swimming.
  • Symptoms associated with glenoid bone loss include inflammation, pain and decreased shoulder function.
  • Surgical approaches presented included two bone grafting techniques: bony increased offset-total shoulder arthroplasty (BIO-TSA) and bony increased offset-reverse shoulder arthroplasty (BIO-RSA).

Orthofix Announces US Launch and First Patient Implants with New fiberFUSE Strip – An Advanced Fiber Bone-Graft Solution Containing Cancellous Bone

Retrieved on: 
Wednesday, July 28, 2021
Medical devices, Surgery, Medical Supplies, Hospitals, FDA, Clinical trials, Practice Management, Biotechnology, Pharmaceutical, Health, Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Skeletal system, Graft, Surgery, Bone, Allotransplantation, Bone grafting, Orthofix, MTF Biologics, ORTHOFIX, MTF BIOLOGICS

(NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the launch and first patient implants with the fiberFUSE Strip , an advanced demineralized fiber bone-graft solution containing cancellous bone.

Key Points: 
  • (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the launch and first patient implants with the fiberFUSE Strip , an advanced demineralized fiber bone-graft solution containing cancellous bone.
  • View the full release here: https://www.businesswire.com/news/home/20210728005105/en/
    Image of the Orthofix fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone.
  • We are pleased to introduce this next-generation formulation in the fiberFUSE allograft line, said Kevin Kenny, President of Orthofix Global Spine.
  • The fiberFUSE Strip delivers a high-quality advanced bone-graft option in a convenient, easy-to-use strip preparation.

Bioventus® Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare Conference

Retrieved on: 
Tuesday, July 27, 2021
Finance, Canaccord Genuity, Genuity, NASDAQ, Bone grafting, Service companies, Investment

DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12 at 3:30 p.m.

Key Points: 
  • DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12 at 3:30 p.m.
  • ET and the Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10 at 9:30 a.m.
  • The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes.
  • Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Vivex Biologics, Inc. Launches VIA Mend™ Synthetic Bone Fillers

Retrieved on: 
Thursday, July 15, 2021
Medical specialties, Surgery, Medicine, Biomaterials, Bone grafting, Oral and maxillofacial surgery, Transplantation medicine, Bioactive glass, Bone mineral, Bone, Collagen

The innovative line of bone graft substitutes can be molded to fill bone defects and supports an environment for bone growth.

Key Points: 
  • The innovative line of bone graft substitutes can be molded to fill bone defects and supports an environment for bone growth.
  • The bone graft matrix is slowly resorbed and replaced by new bone tissue during the natural healing process.
  • "VIVEX isexcited toprovide a next generation synthetic, a bioactive option added to our broad biologics portfolio, delivering surgeon access to newoptionsthat aid inbone formation,"said MichelePablos, MBA, VP and GM of Ortho & Fusion Therapies at VIVEX.
  • "Our next generation VIA Mend Bioactive Strip sets us apart from the many synthetic competitors as it is the perfect trio of Carbonate Apatite bone mineral, highly purified Type I Collagen, and 45S5 Bioactive Glass."

Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Spinal fusion, Bone grafting, Allotransplantation, Vertebral column, Graft, Flowable

DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion and foot & ankle fusion.

Key Points: 
  • DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion and foot & ankle fusion.
  • Developed by our team in collaboration with our tissue bank partner, OSTEOAMP SELECT Flowable comes ready-to-use, and is designed to be delivered in a range of methods, and to provide excellent retention characteristics at the grafting site.
  • OSTEOAMP SELECT Flowable comes in three sizes from 2.5 to 10 cc and is available nationwide.
  • OSTEOAMP, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Biogennix Celebrates a Decade of Innovation and Clinical Success

Retrieved on: 
Tuesday, June 29, 2021
Medical Supplies, Health, Hospitals, Surgery, Manufacturing, Other Manufacturing, Biotechnology, Medical specialties, Clinical medicine, Surgery, Transplantation medicine, Bone grafting, Oral and maxillofacial surgery, Spinal fusion, Bone, Graft

In 2011, Biogennix introduced its novel osteoSPAN fusion kits , which consist of two uniquely-sized porous blocks designed to span the transverse processes during single-level spine fusion procedures.

Key Points: 
  • In 2011, Biogennix introduced its novel osteoSPAN fusion kits , which consist of two uniquely-sized porous blocks designed to span the transverse processes during single-level spine fusion procedures.
  • Its been a highly rewarding ten years of seeing positive clinical outcomes and receiving enthusiastic feedback from surgeons for each of our products, said Dr. Edwin Shors, President of Biogennix.
  • Biogennix is a fully-integrated osteobiologics company headquartered in Irvine, CA which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures.
  • Biogennix is committed to advancing technology behind next-generation bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence.

Elute, Inc. Announces First Clinical Trial Authorization by FDA for Use of Its Antibiotic Eluting Bone Void Filler Product

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Aminoglycoside antibiotics, Tobramycin, Bone grafting, Graft

This is the first FDA authorization to use EP Granules with Tobramycinin patients with such difficult to treat bone infections.

Key Points: 
  • This is the first FDA authorization to use EP Granules with Tobramycinin patients with such difficult to treat bone infections.
  • This type of bone graft would also be attractive in complex revision arthroplasty which is complicated by significant bone deficits.
  • Elute's lead product candidate is EP Granules with Tobramycin, a bone void filler that is designed to provide 8-week, delivery of an antibiotic while allowing growth of new bone.
  • EP Granules with Tobramycin is an investigational device that is limited to investigational use in the United States.

Aziyo Biologics Comments on June 2nd Voluntary Recall of One Lot of its FiberCel Fiber Viable Bone Matrix

Retrieved on: 
Monday, June 7, 2021
Musculoskeletal system, Anatomy, Medical specialties, Bone, Bones, Connective tissue, Skeletal system, Transplantation medicine, Bone grafting, Osteonecrosis of the jaw

At present, the Company has no reason to believe any other units of FiberCel are affected by this situation.

Key Points: 
  • At present, the Company has no reason to believe any other units of FiberCel are affected by this situation.
  • FiberCel is a fiber-based bone repair product made from human tissue and engineered to maintain characteristics of natural tissue.
  • FiberCel provides handling properties that are critical for use as a bone void filler in various orthopedic and spinal procedures.
  • FiberCel contains cancellous bone particles with preserved living cells and demineralized cortical bone fibers to facilitate bone repair and healing.